Neue Studien aus / über Deutschland

Neue Psoriasis-Studien, die bei Pubmed veröffentlicht wurden – mit dem zusätzlichen Stichwort „german“

• Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group
  CONCLUSIONS: Our experience suggests that guselkumab is an effective drug for PsA and PsO patients in clinical practice with good tolerability and no additional safety signals, making it a new therapeutic alternative for the treatment of these combine domains of the disease. These are one of the first and large data from routine clinical practice […]
• Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study
  No abstract
• Genus Lupinus (Fabaceae): a review of ethnobotanical, phytochemical and biological studies
  CONCLUSIONS: The current review provides updated information that could drive the researchers for further studies. The in vitro and in vivo experiments have demonstrated various pharmacological properties. Some pharmacokinetic and toxicological investigations are warranted to ensure its safety and validity for human use.
• Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest
  CONCLUSIONS: FAEs showed a favorable response at 12 months, largely independent of patient characteristics.
• Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
  CONCLUSION: The cumulative probability of drug survival of both IL-17 and IL-23 inhibitors was higher than 75% at 24 months, with risankizumab and guselkumab demonstrating to have overall cumulative probabilities ≥ 90%. Biological agent chosen, prior exposure to biologic agents, higher baseline BMI and PASI values, and absence of family history of psoriasis were identified […]
• Keep an Eye on the Back: Spondyloarthritis in Patients with Acute Anterior Uveitis
  CONCLUSION: We revealed a high prevalence of both, overall and previously undiagnosed, SpA in AAU patients. Therefore, we propose rheumatologic evaluation for all AAU patients with musculoskeletal symptoms.
• Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease
  CONCLUSIONS: ESRD patients with the concomitant psoriasis diagnosis were hospitalized on average 5 years earlier than patients without psoriasis. A higher prevalence of severe life-shortening comorbidities including coronary artery disease and cancer was detected in ESRD patients with psoriasis despite their younger age. Our findings support the understanding of psoriasis as an autoimmune skin disease […]
• The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics
  CONCLUSION: This study reveals a significant impact of the COVID-19 pandemic on the care of dermatological patients in medical offices in Germany. New management modalities and continuous education are needed to improve care in pandemic situations.
• High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
  No abstract
• Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
  CONCLUSIONS: Continued tralokinumab treatment plus TCS as needed provides progressive and sustained improvements in AD signs, symptoms, and health-related QoL over 32 weeks.